Atypical course of severe myoclonic epilepsy of infancy (Dravet syndrome)

Abstract

A clinical observation of a patient with Dravet syndrome caused by SCN1A gene mutation is presented. Dravet syndrome is a severe epileptic encephalopathy that occurs in early childhood, accompanied by seizure polymorphism, drug-resistant course and severe cognitive impairment. The current clinical case confirms the opportunity for drug controlled course of Dravet syndrome. A two-year remission was achieved using polytherapy with antiepileptic drugs. Currently, a complete remission during duotherapy with topiramate in combination with levetiracetam is sustained. The described clinical case also demonstrates preservation of cognitive functions: the child successfully acquires full general education program. It should be noted that upon early relief of epileptic seizures, no cognitive functions become affected.

Keywords

• dravet syndrome
• <i>scn1a</i> gene
• remission
• drug resistance
• cognitive functions
• polytherapy